ODYY - Odyssey Health Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies Portends Competitiveness in Area of Unmet Medical Needs
- A growing chorus of concerns about brain concussions resulting from athletic events is helping to propel new interest in developing pharmaceuticals to treat this “unmet medical need”
- Concussion treatments have largely focused on simple rest, but medical product developer Odyssey Health Inc. is developing a potential treatment to reduce brain inflammation so needed therapy can get to the site of a brain injury
- Odyssey is also developing solutions for other central nervous system troubles, such as the highly fatal childhood disease Niemann-Pick type C, and nerve gas exposure sickness
- The neuropharmaceutical market is forecast to have a great deal of potential, with revenues expected to grow globally from $79.40 billion last year to $125.60 billion by 2029
Concussion head injuries are becoming more widely talked about among sports enthusiasts since two such head injuries in a week’s time required the Miami Dolphins’ quarterback to be carried off the field during a September game and to experience significant memory loss afterward (https://ibn.fm/AiVI6).
Football season naturally lends itself to concerns about concussions, known as traumatic brain injuries or TBIs. During November, sports news outlets have discussed player losses suffered by the...
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at http://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.